scout

WVU Cancer Institute | Strategic Alliance Partners

Latest from WVU Cancer Institute

Bhavana “Tina” Bhatnagar, DO

Dr Bhatnagar discusses the prior and ongoing studies evaluating the addition of uproleselan to standard-of-care regimens for patients with AML, why uproleselan could affect the treatment paradigm across AML subtypes, and the rationale for pursuing minimal residual disease negativity as a clinical end point in AML.